Multicenter, open-label, multi-dose study to evaluate the safety and tolerability in patients with nAMD treated with SCT520FF.
Signed informed consent form.
Age≥45 years, ≤80 years，male or femal.
The study eye must meet the following criteria: Diagnosis of nAMD;Active MNV lesions secondary to nAMD; Total area of all types of lesions ≤12 optic disc areas; BCVA of the study eye 73~19 letters.
Macular-related retinal pigment epithelial tears in the study eye; scar, fibrosis, atrophy or dense subfoveal exudation involving the fovea in the study eye.
Significant APD or opacity of the refractive medium and miosis in the study eye that affect visual acuity or fundus examination.
Aphakia (except intraocular lens) or posterior capsular rupture of the lens in the study eye.
The study eye has any eye diseases or medical history other than nAMD that may affect central vision and/or macular examine.
Sinocelltech Ltd.
Lead sponsor
Tianjin Medical University Eye Hospital
Collaborator